Equities research analysts expect that DURECT Corporation (NASDAQ:DRRX) will report sales of $4.72 million for the current quarter, Zacks reports. Three analysts have provided estimates for DURECT Corporation’s earnings, with estimates ranging from $3.00 million to $7.40 million. DURECT Corporation reported sales of $3.52 million in the same quarter last year, which indicates a positive year over year growth rate of 34.1%. The business is expected to announce its next earnings results on Tuesday, March 13th.

On average, analysts expect that DURECT Corporation will report full year sales of $4.72 million for the current year, with estimates ranging from $16.32 million to $37.03 million. For the next financial year, analysts forecast that the firm will report sales of $21.05 million per share, with estimates ranging from $12.00 million to $37.00 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research analysts that cover DURECT Corporation.

DURECT Corporation (NASDAQ:DRRX) last issued its earnings results on Wednesday, November 1st. The specialty pharmaceutical company reported $0.04 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.05) by $0.09. The business had revenue of $20.75 million during the quarter, compared to analysts’ expectations of $5.09 million. DURECT Corporation had a negative return on equity of 419.65% and a negative net margin of 62.57%.

Several analysts have recently commented on the company. HC Wainwright cut DURECT Corporation from a “buy” rating to a “neutral” rating and set a $3.00 target price for the company. in a research report on Friday, October 20th. Laidlaw decreased their target price on DURECT Corporation from $3.00 to $2.00 and set a “buy” rating for the company in a research report on Friday, October 20th. Stifel Nicolaus cut DURECT Corporation from a “buy” rating to a “hold” rating in a research report on Friday, October 20th. Finally, ValuEngine upgraded DURECT Corporation from a “sell” rating to a “hold” rating in a report on Tuesday, September 26th.

Several large investors have recently made changes to their positions in the stock. TIAA CREF Investment Management LLC raised its holdings in shares of DURECT Corporation by 2.2% during the first quarter. TIAA CREF Investment Management LLC now owns 423,625 shares of the specialty pharmaceutical company’s stock worth $445,000 after acquiring an additional 9,289 shares in the last quarter. The Manufacturers Life Insurance Company raised its holdings in shares of DURECT Corporation by 12.1% during the second quarter. The Manufacturers Life Insurance Company now owns 120,977 shares of the specialty pharmaceutical company’s stock worth $189,000 after acquiring an additional 13,072 shares in the last quarter. Bank of New York Mellon Corp raised its holdings in shares of DURECT Corporation by 4.1% during the second quarter. Bank of New York Mellon Corp now owns 370,387 shares of the specialty pharmaceutical company’s stock worth $578,000 after acquiring an additional 14,553 shares in the last quarter. Voya Investment Management LLC raised its holdings in shares of DURECT Corporation by 22.8% during the second quarter. Voya Investment Management LLC now owns 82,826 shares of the specialty pharmaceutical company’s stock worth $129,000 after acquiring an additional 15,394 shares in the last quarter. Finally, Rhumbline Advisers raised its holdings in shares of DURECT Corporation by 12.0% during the second quarter. Rhumbline Advisers now owns 175,604 shares of the specialty pharmaceutical company’s stock worth $274,000 after acquiring an additional 18,871 shares in the last quarter. Institutional investors and hedge funds own 46.51% of the company’s stock.

Shares of DURECT Corporation (NASDAQ DRRX) traded down $0.05 during trading on Friday, hitting $0.90. The stock had a trading volume of 659,446 shares, compared to its average volume of 1,539,579. The company has a quick ratio of 1.57, a current ratio of 1.67 and a debt-to-equity ratio of 1.46. DURECT Corporation has a 1-year low of $0.74 and a 1-year high of $2.17.

ILLEGAL ACTIVITY WARNING: This story was first posted by Watch List News and is owned by of Watch List News. If you are viewing this story on another website, it was copied illegally and reposted in violation of U.S. and international copyright law. The original version of this story can be read at https://www.watchlistnews.com/analysts-anticipate-durect-corporation-drrx-will-announce-quarterly-sales-of-4-72-million/1683621.html.

DURECT Corporation Company Profile

Durect Corporation is a biopharmaceutical company with research and development programs. The Company’s products candidates include DUR-928, oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. Its other product candidates include POSIMIR (controlled release injection of bupivacaine), REMOXY (oral controlled release oxycodone), ORADUR-ADHD, ELADUR (controlled release injection of bupivicane), Relday (risperidone), ORADUR-based opioid (hydromorphone) and SABER-based ophthalmic.

Get a free copy of the Zacks research report on DURECT Corporation (DRRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for DURECT Corporation (NASDAQ:DRRX)

Receive News & Ratings for DURECT Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DURECT Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.